

Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030

Market Report | 2023-07-06 | 97 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$2950.00
- Enterprisewide Price \$5250.00

Report description:

Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030

Market Overview

The growth of the CEE, Russia & CIS retinal biologics market is attributed to the rising R&D activities in retinal gene therapies, rising efforts for the development of retinal drugs, increasing adoption of retinal biologics for macular degeneration treatment, and increasing prevalence of chronic retinal diseases. However, regulatory obstructions, concerns pertaining to the adverse effects of biologic treatment, and initial high capital investment might hamper the market's growth in the forecast period. Retinal biologics are drugs that are derived from living organisms or may contain derivatives from living organisms to treat a wide range of retinal disorders. Human eyes are highly delicate and can be affected by the minutest of things. Therefore, its security is of high importance. People across the globe are facing some serious retinal health disorders including diabetic retinopathy, infectious retinitis, age-related macular degeneration, macular edema, retinoblastoma, uveitis, retinal degeneration, retinoschisis, and macular hole.

However, the market is being held back by a lack of retinal biologics, dangerous biologic side effects, and limited access to retinal biologics and efficient treatments due to higher costs. Moreover, the market is being challenged by retinal biologics' side effects, which include retinal tears, sickness, and eye pain. The strict regulatory compliances associated with biologics approval imposed by governing authorities are impeding industry growth.

The growing geriatric population and associated diseases such as age-related macular degeneration (AMD) will be a driving factor in this market's growth. Furthermore, increased smoking and alcohol consumption creates several health issues, including diseases such as hypertension and hypercholesterolemia, which damages retinal vessels eventually will benefit the retinal biologics industry. For instance, according to Eurostat Statistics in 2019, Bulgaria recorded 28.7% consumes tobacco in the form of smoking on a daily basis. Moreover, according to the State Agency for the Prevention of Alcohol-Related Problems (PARPA), alcohol consumption increased by 0.23 liter per capita 2019 from 2018.

Market Segmentation

CEE, Russia & CIS retinal biologics market is classified into drug type, distribution channel, indication, and region.

Major Players

The key market players are F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Bayer AG, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

TABLE OF CONTENTS

- 1 EXECUTIVE SUMMARY 11
- 1.1 OVERVIEW 11
- 2 MARKET INTRODUCTION 12
- 2.1 DEFINITION 12
- 2.2 SCOPE OF THE STUDY 12
- 2.3 RESEARCH OBJECTIVE 12
- 2.4 MARKET STRUCTURE 13
- 2.5 ASSUMPTIONS & LIMITATIONS 13
- 3 RESEARCH METHODOLOGY 14
- 3.1 DATA MINING 14
- 3.2 SECONDARY RESEARCH 15
- 3.3 PRIMARY RESEARCH 16
- 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 17
- 3.5 FORECASTING TECHNIQUES 18
- 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 19
- 3.6.1 BOTTOM-UP APPROACH 19
- 3.6.2 TOP-DOWN APPROACH 20
- 3.7 DATA TRIANGULATION 20
- 3.8 VALIDATION 21
- 4 MARKET DYNAMICS 22
- 4.1.1 ANALYSTS' COMMENTS 23
- 5 MARKET FACTOR ANALYSIS 25
- 5.1 VALUE CHAIN ANALYSIS 25
- 5.1.1 R&D 26
- 5.1.2 MANUFACTURING 26
- 5.1.3 DISTRIBUTION & SALES 26
- 5.1.4 POST-SALES MONITORING 26
- 5.2 PORTER'S FIVE FORCES MODEL 27
- 5.2.1 THREAT OF NEW ENTRANTS 27
- 5.2.2 BARGAINING POWER OF SUPPLIERS 27
- 5.2.3 THREAT OF SUBSTITUTES 28
- 5.2.4 BARGAINING POWER OF BUYERS 28
- 5.2.5 INTENSITY OF RIVALRY 28
- 5.3 IMPACT OF COVID-19 ON THE CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET 28
- 5.3.1 IMPACT ON SUPPLY CHAIN 28
- 5.3.2 IMPACT ON PRODUCTION 29
- 5.3.3 IMPACT ON MARKET PLAYERS 29
- 6 CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DRUG CLASS 30
- 6.1 OVERVIEW 30
- 6.2 TNF- α INHIBITOR 31

6.3	VEGF-A ANTAGONIST	32
7	CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY INDICATION	33
7.1	OVERVIEW	33
7.2	MACULAR DEGENERATION	35
7.3	DIABETIC RETINOPATHY	35
7.4	RETINITIS PIGMENTOSA DISEASE	36
7.5	UVEITIS	36
7.6	OTHERS	36
8	CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL	37
8.1	OVERVIEW	37
8.2	HOSPITALS AND CLINICS	39
8.3	PHARMACIES	39
8.4	OTHERS	39
9	CEE, RUSSIA & CIS RETINAL BIOLOGICS MARKET, BY REGION	41
9.1	CEE COUNTRIES	43
9.1.1	POLAND	45
9.1.2	CZECH REPUBLIC	46
9.1.3	BULGARIA	47
9.1.4	HUNGARY	49
9.1.5	ROMANIA	50
9.1.6	REST OF CEE COUNTRIES	52
9.2	RUSSIA	53
9.3	CIS COUNTRIES	55
9.3.1	KAZAKHSTAN	57
9.3.2	BELARUS	58
9.3.3	ARMENIA	59
9.3.4	UZBEKISTAN	60
9.3.5	UKRAINE	61
9.3.6	REST OF CIS COUNTRIES	62
10	COMPETITIVE LANDSCAPE	64
10.1	OVERVIEW	64
10.2	COMPETITIVE BENCHMARKING	65
10.3	KEY DEVELOPMENTS & GROWTH STRATEGIES	66
10.3.1	PRODUCT LAUNCHES/PRODUCT APPROVALS	66
10.4	FINANCIAL MATRIX	66
10.4.1	SALES (USD MILLION), 2021	66
10.4.2	RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021	67
11	COMPANY PROFILES	68
11.1	AMGEN INC.	68
11.1.1	COMPANY OVERVIEW	68
11.1.2	FINANCIAL OVERVIEW	69
11.1.3	PRODUCTS OFFERED	69
11.1.4	KEY DEVELOPMENTS	69
11.1.5	SWOT ANALYSIS	70
11.1.6	KEY STRATEGIES	70
11.2	NOVARTIS AG	71
11.2.1	COMPANY OVERVIEWS	71

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.2.2	FINANCIAL OVERVIEW	72
11.2.3	PRODUCTS OFFERED	73
11.2.4	KEY DEVELOPMENTS	73
11.2.5	SWOT ANALYSIS	73
11.2.6	KEY STRATEGIES	74
11.3	SAMSUNG BIOEPIS CO., LTD	75
11.3.1	COMPANY OVERVIEWS	75
11.3.2	FINANCIAL OVERVIEW	76
11.3.3	PRODUCTS OFFERED	76
11.3.4	KEY DEVELOPMENTS	77
11.3.5	KEY STRATEGIES	77
11.4	INTAS PHARMACEUTICALS LTD.	78
11.4.1	COMPANY OVERVIEW	78
11.4.2	FINANCIAL OVERVIEW	78
11.4.3	PRODUCTS OFFERED	78
11.4.4	KEY DEVELOPMENTS	78
11.4.5	SWOT ANALYSIS	79
11.4.6	KEY STRATEGIES	79
11.5	ABBVIE INC.	80
11.5.1	COMPANY OVERVIEW	80
11.5.2	FINANCIAL OVERVIEW	81
11.5.3	PRODUCTS OFFERED	81
11.5.4	KEY DEVELOPMENTS	82
11.5.5	KEY STRATEGIES	82
11.6	ALIMERA SCIENCES	83
11.6.1	COMPANY OVERVIEW	83
11.6.2	FINANCIAL OVERVIEW	83
11.6.3	PRODUCTS OFFERED	84
11.6.4	KEY DEVELOPMENTS	84
11.6.5	KEY STRATEGIES	84
11.7	BAYER AG	85
11.7.1	COMPANY OVERVIEWS	85
11.7.2	FINANCIAL OVERVIEW	86
11.7.3	PRODUCTS OFFERED	86
11.7.4	KEY DEVELOPMENTS	87
11.7.5	SWOT ANALYSIS	87
11.7.6	KEY STRATEGIES	87
11.8	POLPHARMA BIOLOGICS GROUP	88
11.8.1	COMPANY OVERVIEW	88
11.8.2	FINANCIAL OVERVIEW	88
11.8.3	PRODUCTS OFFERED	88
11.8.4	KEY DEVELOPMENTS	88
11.8.5	KEY STRATEGIES	88
11.9	SUN PHARMACEUTICAL INDUSTRIES LTD.	89
11.9.1	COMPANY OVERVIEW	89
11.9.2	FINANCIAL OVERVIEW	90
11.9.3	PRODUCTS OFFERED	90

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.9.4 KEY DEVELOPMENTS 91
- 11.9.5 KEY STRATEGIES 91
- 11.10 F. HOFFMANN-LA ROCHE LTD 92
- 11.10.1 COMPANY OVERVIEW 92
- 11.10.2 FINANCIAL OVERVIEW 93
- 11.10.3 PRODUCTS OFFERED 93
- 11.10.4 KEY DEVELOPMENTS 93
- 11.10.5 SWOT ANALYSIS 94
- 11.10.6 KEY STRATEGIES 94
- 12 APPENDIX 95
- 12.1 REFERENCES 95
- 12.2 RELATED REPORTS 96
- ?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cee, Russia & Cis Retinal Biologics Market Research Report Forecast to 2030

Market Report | 2023-07-06 | 97 pages | Market Research Future

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2950.00
	Enterprisewide Price	\$5250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-23"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com